Contineum Therapeutics (NASDAQ:CTNM) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Contineum Therapeutics (NASDAQ:CTNM) had its price objective lifted by stock analysts at Robert W. Baird from $14.00 to $20.00 in a report issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s target price would indicate a potential upside of 44.09% from the company’s current price.

Several other equities analysts have also issued reports on CTNM. Wall Street Zen upgraded Contineum Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Leerink Partners initiated coverage on Contineum Therapeutics in a research note on Thursday, November 13th. They set an “outperform” rating and a $22.00 price objective for the company. Royal Bank Of Canada cut their target price on shares of Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating on the stock in a report on Friday, November 21st. Morgan Stanley reiterated an “equal weight” rating and set a $14.00 price target (down from $23.00) on shares of Contineum Therapeutics in a report on Thursday, January 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Contineum Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $20.20.

Contineum Therapeutics Stock Performance

Shares of NASDAQ:CTNM opened at $13.88 on Friday. The company has a fifty day moving average of $13.36 and a 200-day moving average of $12.05. The company has a market capitalization of $405.02 million, a PE ratio of -6.37 and a beta of 1.07. Contineum Therapeutics has a 52-week low of $3.35 and a 52-week high of $16.33.

Contineum Therapeutics (NASDAQ:CTNM) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.01. On average, equities analysts forecast that Contineum Therapeutics will post -2.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Strs Ohio purchased a new position in Contineum Therapeutics during the first quarter valued at $27,000. China Universal Asset Management Co. Ltd. purchased a new stake in Contineum Therapeutics in the fourth quarter worth about $43,000. Qube Research & Technologies Ltd bought a new position in shares of Contineum Therapeutics during the second quarter valued at approximately $43,000. Marex Group plc purchased a new position in shares of Contineum Therapeutics during the second quarter valued at approximately $45,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Contineum Therapeutics during the second quarter valued at approximately $76,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.